These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 3502367)

  • 1. [Quinolones: antimicrobials for the 90s].
    Timerman A
    AMB Rev Assoc Med Bras; 1987; 33(5-6):81-2. PubMed ID: 3502367
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in vitro activity of ofloxacin (RU 43 280) and other quinolone derivatives against 722 bacteria of clinical interest.
    Santos Ferreira M; Vital J
    Chemioterapia; 1987 Jun; 6(2 Suppl):145-7. PubMed ID: 2908239
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nitrofurans: a modern treatment for uncomplicated urinary infections?].
    Cahen P; Honderlick P
    Pathol Biol (Paris); 2000 Jun; 48(5):470-1. PubMed ID: 10949843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selection of Escherichia coli mutants with decreased susceptibility to norfloxacin.
    Forsgren A; Striby AC
    Scand J Infect Dis; 1988; 20(5):531-4. PubMed ID: 3065926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A study of the in vitro sensitivity of Enterobacteriaceae and Pseudomonas aeruginosa to 7 antimicrobial agents].
    Lynch MB; Mimica I; Valenzuela MC; Vilches A; Abarca S
    Rev Med Chil; 1972 Jan; 100(1):14-5. PubMed ID: 4622217
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro sensitivity pattern of gram negative pathogens to nalidixic acid.
    Chitkara YK
    Indian J Pathol Bacteriol; 1969 Oct; 12(4):162-8. PubMed ID: 4990210
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro activity of ciprofloxacin, norfloxacin, and ofloxacin against multi-resistant Enterobacteriaceae.
    Niculescu E; Wagener H
    Chemioterapia; 1987 Jun; 6(2 Suppl):132-3. PubMed ID: 3509369
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective decontamination of the digestive tract by norfloxacin. A preliminary report.
    Pecquet SS; Andremont AO; Tancrède CH
    Prog Clin Biol Res; 1985; 181():255-8. PubMed ID: 3161086
    [No Abstract]   [Full Text] [Related]  

  • 14. [Resistance to new quinolones among the enterobacteria].
    Liassine N; Chelfi A; Rahal K
    Arch Inst Pasteur Alger; 1992; 58():85-94. PubMed ID: 1309147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Growing incidence of nalidixic acid resistance and sensitivity to quinolones in Salmonella typhimurium strains isolated from man or animal].
    Heurtin-Le Corre C; Donnio PY; Bonnier M; Travert MF; Lacourt A; Avril JL
    Pathol Biol (Paris); 1998 Oct; 46(8):587-90. PubMed ID: 9871929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.
    Cruciani M; Monzillo V; Navarra A; Tinelli C; Concia E
    Drugs Exp Clin Res; 1988; 14(8):533-7. PubMed ID: 3150350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalidixic acid in urinary infection.
    Neogy KN; De MS; Chatterjee ML
    Bull Calcutta Sch Trop Med; 1968 Jan; 16(1):11-2. PubMed ID: 4890385
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of nalidixic acid activity on 3186 strains of Gram negative bacilli. Application to the treatment of urinary infections].
    Chamfeuil R; Curcier H
    Presse Med (1893); 1969 Nov; 77(48):1763-4. PubMed ID: 4903534
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.